Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.
D000818:Animals; D000970:Antineoplastic Agents; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D001835:Body Weight / Q000187:drug effects; D002219:Carbamates / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives; D014529:Uridine / Q000494:pharmacology*
D000970:Antineoplastic Agents; D002219:Carbamates; D009943:Organophosphorus Compounds; D001224:Aspartic Acid; C013195:sparfosic acid; D010746:Phosphonoacetic Acid; D014529:Uridine